Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

Kaira, Kyoichi; Tomizawa, Yoshio; Imai, Hisao; Sakurai, Reiko; Matsuura, Makoto; Yoshii, Akihiro; Ochiai, Mai; Kotake, Mie; Ebara, Takeshi; Saitoh, Jun‐ichi; Sunaga, Noriaki; Minato, Koichi; Saito, Ryusei; Hisada, Takeshi

doi:10.1007/s00280-016-3217-1

Cited by 15 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Kurtul N. et al 18 increased SPARC expression was associated with poor prognosis when patients were treated with nab-paclitaxel and concurrent radiotherapy. In the study by Kaira K. et al 19 a combination of carboplatin and nab-paclitaxel plus radiotherapy was administered as first line in unresectable stage III NSCLC with safety and efficacy in patients ≤65 years of age. Nab-paclitaxel can be used in NSCLC as first line treatment as an alternative to best supportive care in the group of the “elderly” ≥75 years of age.…”

Section: Discussionmentioning

confidence: 99%

Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old

et al. 2017

View full text Add to dashboard Cite

Introduction: Lung cancer is still the leading cause of cancer among cancer patients. Although there are novel therapies as second line treatment for NSCLC, there is an issue for elderly patients. Patients and Methods: We collected retrospectively data from 60 patients >75 years of age. Thirty of these patients received nab-paclitaxel and first line treatment and were compared to thirty patients that received only best supportive care. Results: The median life of patients at the date of disease progression, although increased by the administration of the drug (92 days versus 70) was not confirmed statistically significantly (Mann-Whitney test: W = 280, p = 0.138). The administration of drug seems to keep stable the biological condition of patients (McNemar's test: χ2 = 0.033, p = 0.99). Patients with chemotherapy the death rate was increased by 50% as compared to those with best supportive care (12 vs 8), the median life until the unfortunate event surpassed statistically significantly the latter (150 days of life as compared to 108, Mann-Whitney test: W = 57.5, p = 0.045). Discussion: Nab-paclitaxel as a monotherapy could be considered as a first line treatment option for patients > 75 years of age without any previous cardiological medical history when compared to best supportive care.

show abstract

Section: Discussionmentioning

confidence: 99%

Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The most well‐studied NP example is the clinical use of NP albumin (nab)‐bound paclitaxel (nab‐PTX) for a variety of solid tumor malignancies, such as NSCLC, breast cancer, and pancreatic cancer. A phase 1 trial in advanced NSCLC showed that the combination of radiotherapy, nab‐PTX, and carboplatin produced an objective response in 71% of patients with acceptable toxicity . A phase 2 trial using nab‐PTX in 42 patients with recurrent, refractory ovarian cancer reported a 23% response rate, a 36% stable disease rate, a median OS of 17.4 months, and no grade 4 or higher adverse events .…”

Section: Emerging Therapeutic Drug‐delivery Strategies For Lrrmentioning

confidence: 99%

“…A phase 1 trial in advanced NSCLC showed that the combination of radiotherapy, nab-PTX, and carboplatin produced an objective response in 71% of patients with acceptable toxicity. 125 A phase 2 trial using nab-PTX in 42 patients with recurrent, refractory ovarian cancer reported a 23% response rate, a 36% stable disease rate, a median OS of 17.4 months, and no grade 4 or higher adverse events. 126 Polymeric NPs are particularly of interest, because they can be designed to be responsive to various triggering stimuli, including microenvironmental changes in temperature, pH, or hypoxia as well as magnetic or ultrasound activation.…”

Section: Peritoneal Surface Malignanciesmentioning

confidence: 99%

Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies

Mahvi

Liu

Grinstaff

et al. 2018

CA A Cancer J Clinicians

262

167

View full text Add to dashboard Cite

Locoregional recurrence negatively impacts both long-term survival and quality of life for a number of malignancies. For appropriate-risk patients with an isolated, resectable local recurrence, surgery represents the only potentially curative therapy. However, oncologic outcomes remain inferior for patients with locally recurrent disease even after macroscopically complete resection. Unfortunately, these operations are often extensive with significant perioperative morbidity and mortality. This review highlights selected malignancies (mesothelioma, sarcoma, lung cancer, breast cancer, rectal cancer, peritoneal surface malignancies) in which surgical resection is a key treatment modality and where local recurrence plays a significant role in overall oncologic outcome with regards to survival and quality of life. For each type of cancer, the current, state-of-the-art treatment strategies and their outcomes are assessed. The need for additional therapeutic options is presented given the limitations of the current standard therapies. New and emerging treatment modalities, including polymer films and nanoparticles, are highlighted as potential future solutions for both prevention and treatment of locally recurrent cancers. Finally, we identify additional clinical and research opportunities, and propose future research strategies based on the varying patterns of local recurrence among the different cancers.

show abstract

“…Moreover, a preclinical study showed that combining nab-PTX with RT represents an improvement in chemoradiotherapy [12]. Kaira et al reported a phase I study of weekly nab-PTX with carboplatin and RT in patients with LA-NSCLC [13]. In that study, the recommended doses were nab-PTX of 80 mg/m 2 and carboplatin of area under the time-concentration curve (AUC) 2 mg/mL/min.…”

Section: Introductionmentioning

confidence: 99%

A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non–small-cell Lung Cancer

Tanaka

Hasegawa

Makiguchi

et al. 2021

Clinical Lung Cancer

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

Abstract: This regimen is feasible and well tolerated for the treatment of patients with unresectable locally advanced NSCLC.

Cited by 15 publications

References 10 publications

Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old

Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old

Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies

A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non–small-cell Lung Cancer

Contact Info

Product

Resources

About